SELECTA BIOSCIENCES INC (SELB)
US8162121045 - Common Stock
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track...
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up...
Selecta Biosciences Announces Merger with Cartesian Therapeutics
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly...
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
Selecta Biosciences files for $200M mixed shelf (NASDAQ:SELB)
Selecta Biosciences files prospectus for a mixed shelf offering of up to $xx million. Not an offer to sell securities.
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on...
Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)
Acumen (ABOS), Establishment Labs (ESTA), Arcus (RCUS) and BridgeBio (BBIO) are four of BTIG's top picks for small and mid-cap healthcare stocks for 2H 2023. Read more here.
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically...
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!
Selecta stock surges ~20% as gout drug SEL-212 meets main goal in 2 trials
Selecta Biosciences (SELB) and Swedish Orphan Biovitrum (Sobi) (BIOVF) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout.Gout is...
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo...
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response...
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll...
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
Selecta Biosciences stock rises 10% on license deal with Astellas for Xork
Selecta Biosciences (SELB) stock rose ~10% on Monday after the company said it signed an exclusive licensing and development agreement with Astellas Pharma (ALPMF) (ALPMY) for...
Selecta Biosciences Provides Business Update and Outlook for 2023
- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for...
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB, President and CEO: Carsten Brunn, Ph.D., "Selecta"), and Astellas Pharma Inc. (TSE: 4503, President...
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
– IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address...
Selecta Biosciences appoints Protara Therapeutics's Blaine Davis as new CFO (NASDAQ:SELB)
Selecta Biosciences (SELB) has named Blaine Davis as the company's new chief financial officer, replacing Kevin Tan, effective Nov